Метаанализ эффективности и безопасности использования линии препаратов Магне В6 в гинекологии

Abstract

Magnesium deficiency is an important factor in the etiopathogenesis of premenstrual syndrome (PMS) and the cause of complications in patients receiving menopausal hormone therapy (MHT).Materials and methods. The results of a meta-analysis of 8 clinical studies on the use of magnesium preparations in the form of organic salts for oral administration.Conclusions. PMS therapy includes the use of drugs, e.g. magnesium which is associated with a reduction in PMS symptoms: irritability, and emotional lability (5 studies, n=775, OR 0,24, 95% CI 0,20-0,29, p<10-33), depression (5 studies, n=537, OR=0,53, 95% CI 0,44-0,63, p<10-20), headache (5 studies, n=219,OR 0,48, 95% CI 0,37-0,61, p<10-15), and mastalgia mammalgia (5 studies, n=717, OR 0,23, 95% CI 0,19-0,27, p<10-38), bloating, flatulence (5 studies,n=489, OR 0,53, 95% CI 0,44-0,63, p<10-12), swelling, a feeling of fullness (5 studies, n=262, OR 0,36, 95% CI 0,28-0,46, p<10-25), tearfulness (3 studies, n=432, OR 0,51, 95% CI 0,42-0,61, p<10-35), sweating (3 studies, n=190, OR 0,20, 95% CI 0,14-0,28, p<10-27). Side effects associated with taking drugs were noted. In general, the meta substantiates of widespread use of preparations based on organic magnesium salts (citrate, lactate and pidolate) in the treatment of PMS and accompanied MGT.